TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24268371
Drug: Standard 14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 14-day quadruple treatment (Rabeprazole 20mg-bid, bismuth subcitrate 120 mg-qid, Tetracycline 500 mg-qid, Metronidazole 500 mg-tid for 2 weeks)
Study: 24268371
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 5 days)
Study: 20199521
Drug: Rufinamide (25-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide (25-60 mg/kg/day)
Study: 31592939
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (1.6 × 10 colony‐forming units of Lactobacillus rhamnosus capsules)
Study: 31592939
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (maltodextrin capsules)
Study: 25401501
Drug: Serum selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum selenium deficiency (<85 μg/L) pre-ART
Study: 22863643
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release therapy + Kinesiotherapy
Study: 16320441
Drug: 12-step measures
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step measures thresholds (e.g., >20 meetings for alcoholics, 2 or more nondrinkers in the social network)
Study: 674624
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g iopanoic acid administered over 6 hours (0.5 g/hour)
Study: 674624
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g iopanoic acid administered in a single dose
Study: 20625738
Drug: Sorafenib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib and erlotinib treatment
Study: 18928103
Drug: Buzhong Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buzhong Yiqi Pill (BYP) combined with imodium
Study: 10934092
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension via face mask 0.25 mg daily
Study: 10934092
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension via face mask 0.25 mg twice daily
Study: 10934092
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension via face mask 0.5 mg twice daily
Study: 10934092
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension via mouthpiece 1.0 mg daily
Study: 10934092
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension via face mask or mouthpiece
Study: 8240462
Drug: Garlic-ginkgo combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic-ginkgo combination product (Allium plus)
Study: 27431234
Drug: Tribendimidine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 25 mg
Study: 27431234
Drug: Tribendimidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 200 mg
Study: 27472949
Drug: Tribendimidine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 50 mg (children)
Study: 27472949
Drug: Tribendimidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 100 mg (children)
Study: 23857972
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy (2,500 mg/m2)
Study: 15836977
Drug: Long-term opioid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term opioid administration in chronic pain patients
Study: 1891488
Drug: Individual versus
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual versus fixed dose of nicotine patches
Study: 31658293
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml dye injection
Study: 31658293
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml dye injection
Study: 30002088
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 0.5 mL 0.1% nitroglycerin
Study: 406627
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methylphenidate
Study: 21597989
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylphenidate
Study: 21597989
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylphenidate
Study: 1282609
Drug: NIF (nifedipine)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIF (nifedipine) 40-60 mg/day
Study: 1282609
Drug: NIS (nisoldipine)
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIS (nisoldipine) 10-20 mg/day
Study: 29402815
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal surface anesthesia
Study: 26502371
Drug: ALA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA treatment in donor and recipient (DR group)
Study: 26502371
Drug: Recipient ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recipient ALA treatment
Study: 25329228
Drug: EPA-enriched supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-enriched supplementation (2.2 g EPA)
Study: 7536072
Drug: G-CSF after
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF after autologous BMT
Study: 28783871
Drug: Ozanimod (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (escalated from 0.25 to 2 mg over 14 days)
Study: 18958837
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (including glucose-insulin-potassium (GIK) approaches and non-GIK approaches)
Study: 8836309
Drug: Posatirelin 10
Normalized name: Rovatirelin
DrugBank: Rovatirelin (DB15338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posatirelin 10 mg/ml, administered intramuscularly once a day for 12 weeks
Study: 8836309
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered intramuscularly once a day for 12 weeks
Study: 8836309
Drug: Posatirelin 10
Normalized name: Rovatirelin
DrugBank: Rovatirelin (DB15338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posatirelin 10 mg/ml
Study: 15699241
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol/d (one drink)
Study: 15699241
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol/d (2 drinks)
Study: 2200174
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of maintenance dose of CsA (group 1, n = 27)
Study: 90280
Drug: Various cancer
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various cancer treatments under study
Study: 26456905
Drug: Grazoprevir and
Normalized name: elbasvir and grazoprevir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir and elbasvir (combined immediate treatment group and intensive pharmacokinetic population)
Study: 26456905
Drug: Grazoprevir and
Normalized name: elbasvir and grazoprevir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir and elbasvir (immediate treatment group)
Study: 23252963
Drug: Progesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (300 mg/d at bedtime)
Study: 19926622
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/d (group R, n = 20)
Study: 19926622
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20)
Study: 19926622
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20)
Study: 10433584
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine
Study: 1508357
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 275 mg i.m. administered at the end of surgery and after 12 hours
Study: 1508357
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 550 mg i.m. administered at the end of surgery and after 12 hours
Study: 6379708
Drug: Exercise tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise tolerance training (weekly attendance and daily home exercises)
Study: 25617625
Drug: Rg1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg1 (5 mg)
Study: 23432159
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical fusidic acid use
Study: 16526986
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus androgen deprivation therapy (ADT)
Study: 12714022
Drug: Testosterone 60
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 60 mg via buccal route
Study: 8617190
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/day of zinc as zinc sulfate)
Study: 31102079
Drug: Poster highlighting
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poster highlighting the futility of antibiotic treatment for colds
Study: 18606932
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of fortified spread (FS25)
Study: 6851968
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of norethisterone
Study: 22270141
Drug: Hyoscine N‐butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N‐butylbromide (HBB) intravenous (i.v.)
Study: 22270141
Drug: Glucagon (GLU)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon (GLU) intravenous (i.v.)
Study: 22270141
Drug: Hyoscine N‐butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N‐butylbromide (HBB) intramuscular (i.m.)
Study: 22270141
Drug: Glucagon (GLU)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon (GLU) intramuscular (i.m.)
Study: 19844176
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) 40 mg once daily
Study: 19844176
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 IU twice daily
Study: 16222402
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g/kg for 5 days and 0.07 g/kg thereafter) with resistance training
Study: 8703248
Drug: Budesonide turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide turbuhaler (200 micrograms/dose), two inhalations, twice daily for eight weeks
Study: 8703248
Drug: Budesonide turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide turbuhaler (200 micrograms/dose)
Study: 2192717
Drug: bezafibrate retard
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate retard plus colestyramine (24 g/d)
Study: 25873067
Drug: Panic Control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic Control Treatment
Study: 19890182
Drug: Traditional medical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medical therapies models (e.g., quality-adjusted life years)
Study: 11557913
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g activated charcoal as a suspension
Study: 11557913
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL water (control)
Study: 2916871
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg single dose)
Study: 3292811
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day for two weeks)
Study: 3292811
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day for long-term use, average 13.9 months)
Study: 28601497
Drug: Once-monthly paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-monthly paliperidone palmitate (PP1M)
Study: 31434507
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg once daily)
Study: 28288972
Drug: Synthetic disease-modifying
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic disease-modifying antirheumatic drugs
Study: 25733653
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis at a dose of 10^9 colony-forming units/d
Study: 8511727
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 1500 micrograms twice daily
Study: 8511727
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 40 mg per day
Study: 3493852
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg X kg‐1)
Study: 3493852
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg X kg‐1)
Study: 22751603
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg
Study: 24253785
Drug: Kiva implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiva implant with low viscosity PMMA
Study: 18587715
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment including ACE inhibitors, AT1 blockers, statins, dietary counseling, and smoking cessation programs.
Study: 18587715
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment including steroids or steroids plus cyclophosphamide/azathioprine, in addition to supportive treatment.
Study: 10963286
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0, 1, and 2 months
Study: 10963286
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0 and 1 months
Study: 9513799
Drug: Buprenorphine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.6 mg)
Study: 24217129
Drug: VRE-DCS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRE-DCS (100 mg D-cycloserine administered 90 min before each weekly VRE session)
Study: 24217129
Drug: VRE-placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRE-placebo (placebo administered 90 min before each weekly VRE session)
Study: 20484012
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of octreotide (a somatostatin analog)
Study: 25132340
Drug: Intradetrusor onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intradetrusor onabotulinumtoxinA injections
Study: 11063636
Drug: Ifosfamide-cisplatin (ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide-cisplatin (ifosfamide with cisplatin 20 mg/m(2)/day for 5 days)
Study: 8885752
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution plus physiologic glucose
Study: 30282662
Drug: Mind-body therapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body therapy (MBT) intervention; duration: two days
Study: 26566681
Drug: Methadone syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone syrup
Study: 15986086
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (placebo group)
Study: 12697078
Drug: Ertapenem, 1
Normalized name: Ertapenem, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem, 1 g once a day
Study: 12697078
Drug: Piperacillin-tazobactam, 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam, 3.375 g every 6 hours
Study: 10952480
Drug: Intravenous methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylene blue (100 mg)
Study: 10952480
Drug: Oral methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylene blue (100 mg)
Study: 24612148
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily for 12 weeks
Study: 14611917
Drug: Sequential platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential platinum-based chemoradiotherapy
Study: 14611917
Drug: Molecular therapies
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular therapies integrated with chemoradiotherapy
Study: 10960397
Drug: Intraperitoneal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Study: 10960397
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Study: 1535505
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day 4‐HPR for 5 years
Study: 28683796
Drug: Dapagliflozin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin group (750 mg/day metformin + 5 mg/day dapagliflozin)
Study: 28683796
Drug: Metformin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin group (1500 mg/day metformin)
Study: 25085686
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg kg(‐1)
Study: 17130411
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 to 600 mg/day
Study: 16573707
Drug: Phosphodiesterase 5
Normalized name: Phosphodiesterase 5 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase 5 inhibitors (PDE5-Is)
Study: 31898212
Drug: Selective-serotonin reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective-serotonin reuptake inhibitors (SSRIs)
Study: 12773645
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily) plus optimized background regimen
Study: 11145490
Drug: Research associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research associated with risk or discomfort greater than standard treatment
Study: 3560028
Drug: Colon preparation
Normalized name: porcine colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon preparation involving wash-out enemas
Study: 3560028
Drug: Colon preparation
Normalized name: porcine colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon preparation involving laxatives
Study: 3560028
Drug: Colon preparation
Normalized name: porcine colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon preparation involving residue-free diet
Study: 3560028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three methods (residue-free diet, laxatives, wash-out enemas)
Study: 3560028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other colon preparations)
Study: 27027541
Drug: Amphetamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine treatment for 3 weeks
Study: 24772504
Drug: Improved patient
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved patient compliance before treatment
Study: 24772504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without compliance improvement)
Study: 22535855
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (up to 5 weekly messages)
Study: 19033823
Drug: Intrabrachial Lys‐[Leu8]‐des‐Arg9‐bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabrachial Lys‐[Leu8]‐des‐Arg9‐bradykinin (B1 antagonist)
Study: 19033823
Drug: Bradykinin (B2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin (B2 agonist)
Study: 12651680
Drug: Fentanyl (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (125 microg initial dose, testing interval 5 microg)
Study: 9895070
Drug: TIVA/TCI (propofol-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA/TCI (propofol-based TCI system and continuous administration of remifentanil)
Study: 9895070
Drug: Isoflurane (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane (inhaled anesthesia with isoflurane, fentanyl, and N2O)
Study: 9895070
Drug: Standard propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard propofol (fentanyl and N2O with continuous infusion of propofol using a standard delivery system)
Study: 8887038
Drug: High-dose intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intraperitoneal aprotinin treatment (aprotinin group, n = 22)